Gossamer bio announces inducement grant under nasdaq listing rule 5635(c)(4)

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced that the compensation committee of gossamer's board of directors approved the grant, effective january 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the company's com.
GOSS Ratings Summary
GOSS Quant Ranking